Compounds > ipragliflozin
Page last updated: 2024-08-02 16:58:10

ipragliflozin

Description

ipragliflozin : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID10453870
CHEMBL ID2018096
SCHEMBL ID337645
CHEBI ID134724
MeSH IDM0574629

Synonyms (44)

Synonym
CHEBI:134724
ipragliflozin ,
D10196
ipragliflozin (inn)
bdbm50381554
asp-1941
asp1941
ipragliflozin [inn]
3n2n8oor7x ,
761423-87-4
asp 1941
suglat
(1s)-1,5-anhydro-1-c-(3-((1-benzothiophen-2-yl)methyl)-4-fluorophenyl)-d-glucitol
(1s)-1,5-anhydro-1-(3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl)-d-glucitol
unii-3n2n8oor7x
ipragliflozin [who-dd]
ipragliflozin [mi]
d-glucitol, 1,5-anhydro-1-c-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-, (1s)-
CHEMBL2018096 ,
S8637
HY-14894
SCHEMBL337645
AHFWIQIYAXSLBA-RQXATKFSSA-N
(1s)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-d-glucitol
(1s)-1,5-anhydro-1-c-[3-(1-benzothiophene-2-ylmethyl)-4-fluorophenyl]-d-glucitol
gtpl9394
(2s,3r,4r,5s,6r)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
AC-29008
AKOS025405258
(2s,3r,4r,5s,6r)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4r,5s,6r)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s)-1,5-anhydro-1-c-[3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl]-d-glucitol
ipragliflozin (asp1941)
EX-A2770
DB11698
AS-39358
Q17193526
d-glucitol,1,5-anhydro-1-c-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1s)-
ipragliflozin-l-proline
AMY38779
CCG-268693
NCGC00378606-02
d-glucitol, 1,5-anhydro-1-c-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1s)-; (1s)-1,5-anhydro-1-c-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-d-glucitol; asp 1941; ipragliflozin; suglat
DTXSID701032738

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Sodium/glucose cotransporter 1Homo sapiens (human)IC501.8760AID1546222
Sodium/glucose cotransporter 2Homo sapiens (human)IC500.0076AID1396969; AID1413445; AID1546223; AID657588

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Sodium/glucose cotransporter 1Homo sapiens (human)EC501.9000AID1546902
Sodium/glucose cotransporter 2Homo sapiens (human)EC500.0074AID1546903

Bioassays (34)

Assay IDTitleYearJournalArticle
AID657589Selectivity index, ratio of IC50 for human SGLT1 to IC50 for human SGLT22012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657599AUC (0 to 24 hrs) in Sprague-Dawley rat at 1 mg/kg, po2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657590Antidiabetic activity in mouse assessed as induction of urinary glucose excretion at 0.01 to 10 mg/kg, po administered as single dose after 24 hrs2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657592Antidiabetic activity in KKAy mouse type 2 diabetic model assessed as decrease in blood glucose level at 0.1 to 1 mg/kg, po administered as single dose after 8 hrs2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657596Tmax in Sprague-Dawley rat at 1 mg/kg, po2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1546225Antidiabetic activity in human T2DM patients assessed as fasting blood glucose level at 50 mg, po for 24 weeks2019European journal of medicinal chemistry, Dec-15, Volume: 184ISSN: 1768-3254Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID657601AUC (infinity) in Sprague-Dawley rat at 1 mg/kg, po2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1546223Inhibition of human SGLT22019European journal of medicinal chemistry, Dec-15, Volume: 184ISSN: 1768-3254Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID1546902Inhibition of SGLT1 (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
ISSN: 1520-4804		The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID657598AUC (0 to 24 hrs) in Sprague-Dawley rat at 0.3 mg/kg, iv2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1396969Inhibition of SGLT2 (unknown origin)2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
ISSN: 1464-3391		Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.
AID657603Oral bioavailability in Sprague-Dawley rat at 1 mg/kg2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657591Antidiabetic activity in KKAy mouse type 2 diabetic model assessed as induction of urinary glucose excretion at 0.01 to 10 mg/kg, po administered as single dose after 24 hrs2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657588Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]AMG accumulation after 2 hrs by scintillation counting2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657597Cmax in Sprague-Dawley rat at 1 mg/kg, po2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657600AUC (infinity) in Sprague-Dawley rat at 0.3 mg/kg, iv2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1546222Inhibition of human SGLT12019European journal of medicinal chemistry, Dec-15, Volume: 184ISSN: 1768-3254Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID1546232Selectivity ratio of IC50 for inhibition of human SGLT1 to IC50 for inhibition of human SGLT22019European journal of medicinal chemistry, Dec-15, Volume: 184ISSN: 1768-3254Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID1413446Selectivity ratio of IC50 for recombinant human full-length SGLT1 expressed in CHO cells to IC50 for recombinant human full-length SGLT2 expressed in CHO cells2018MedChemComm, Aug-01, Volume: 9, Issue:8
ISSN: 2040-2511		Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
AID1546224Antidiabetic activity in human T2DM patients assessed as reduction in HbA1c level at 50 mg, po for 24 weeks relative to control2019European journal of medicinal chemistry, Dec-15, Volume: 184ISSN: 1768-3254Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID657604Volume of distribution at steady state in Sprague-Dawley rat at 0.3 mg/kg, iv2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1546226Antidiabetic activity in human T2DM patients assessed as reduction in body weight at 50 mg, po for 24 weeks2019European journal of medicinal chemistry, Dec-15, Volume: 184ISSN: 1768-3254Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID657593Antidiabetic activity in streptozotocin-induced Sprague-Dawley rat type 1 diabetic model assessed as decrease in blood glucose level at 0.1 to 1 mg/kg, po administered as single dose after 8 hrs2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1413445Inhibition of recombinant human full-length SGLT2 expressed in CHO cells assessed as decrease in [14C]-AMG uptake measured after 2 hrs by topcount scintillation counting method2018MedChemComm, Aug-01, Volume: 9, Issue:8
ISSN: 2040-2511		Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
AID1546903Inhibition of SGLT2 (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
ISSN: 1520-4804		The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID657594Half life in Sprague-Dawley rat at 0.3 mg/kg, iv2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657595Half life in Sprague-Dawley rat at 1 mg/kg, po2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID657602Total clearance in Sprague-Dawley rat at 0.3 mg/kg, iv2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
ISSN: 1464-3391		Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
AID1346965Human Sodium/glucose cotransporter 2 (Hexose transporter family)2012Naunyn-Schmiedeberg's archives of pharmacology, Apr, Volume: 385, Issue:4
ISSN: 1432-1912		Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
AID1346942Mouse Sodium/glucose cotransporter 1 (Hexose transporter family)2012Naunyn-Schmiedeberg's archives of pharmacology, Apr, Volume: 385, Issue:4
ISSN: 1432-1912		Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
AID1346952Rat Sodium/glucose cotransporter 2 (Hexose transporter family)2012Naunyn-Schmiedeberg's archives of pharmacology, Apr, Volume: 385, Issue:4
ISSN: 1432-1912		Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
AID1346969Mouse Sodium/glucose cotransporter 2 (Hexose transporter family)2012Naunyn-Schmiedeberg's archives of pharmacology, Apr, Volume: 385, Issue:4
ISSN: 1432-1912		Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
AID1346974Rat Sodium/glucose cotransporter 1 (Hexose transporter family)2012Naunyn-Schmiedeberg's archives of pharmacology, Apr, Volume: 385, Issue:4
ISSN: 1432-1912		Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
AID1346950Human Sodium/glucose cotransporter 1 (Hexose transporter family)2012Naunyn-Schmiedeberg's archives of pharmacology, Apr, Volume: 385, Issue:4
ISSN: 1432-1912		Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Research

Studies (172)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's130 (75.58)24.3611
2020's42 (24.42)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (25.71%)5.53%
Reviews24 (13.71%)6.00%
Case Studies14 (8.00%)4.05%
Observational7 (4.00%)0.25%
Other85 (48.57%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
tomatine
0
alkaloid antibiotic;
glycoalkaloid;
glycoside;
steroid alkaloid;
tetrasaccharide derivative		antifungal agent;
immunological adjuvant;
phytotoxin		00low000000
sucrose octaacetate
0
glycoside00low000000
phenyl beta-d-glucopyranoside
0
glycoside00low000000
thiocolchicoside
0
glycoside00low000000
plumieride
0
glycoside00low000000
chrysomycin a
0
glycoside00low000000
convicine
0
glycoside00low000000
gentiopicroside
0
glycoside00low000000
picein
0
glycoside00low000000
populin
0
glycoside00low000000
skimmin
0
coumarins;
glycoside		00low000000
arctiin
0
glycoside;
lignan		00low000000
dodecyl-beta-d-maltoside
0
disaccharide derivative;
glycoside		detergent00low000000
gastrodin
0
glycoside00low000000
phenylglucuronide
0
glycoside00low000000
nepitrin
0
flavonoids;
glycoside		00low000000
4-methylumbelliferylcellobioside
0
coumarins;
glycoside		00low000000
bungeiside c
0
glycoside00low000000
4-(rhamnosyloxy)phenylacetonitrile
0
glycoside00low000000
lac dye
0
disaccharide derivative;
glycoside;
monoazo compound		dye00low000000
leiocarposide
0
glycoside00low000000
rhodioloside
0
glycoside00low000000
cirsimarin
0
flavonoids;
glycoside		00low000000
sweroside
0
glycoside00low000000
aloenin
0
glycoside00low000000
tracheloside
0
glycoside;
lignan		metabolite00low000000
tribenoside
0
glycoside00low000000
beta-indol-3-yl-glucoside
0
glycoside;
indoles		00low000000
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one
0
glycoside00low000000
levanbiose
0
glycoside00low000000
ranunculin
0
glycoside00low000000
swertiamarin
0
glycoside00low000000
Rhododendrin
0
glycoside00low000000
tremulacin
0
glycoside00low000000
acarbose
0
amino cyclitol;
glycoside		00low000000
isopropyl-beta-galactopyranoside
0
glycoside00low000000
acarviosine
0
amino cyclitol;
glycoside		00low000000
hidrosmin
0
flavonoids;
glycoside		00low000000
glucovanillin
0
glycoside00low000000
resveratrol-4'-o-glucuronide
0
glycoside;
stilbenoid		00low000000
chartreusin
0
benzochromenone;
glycoside		00low000000
isorhapontin
0
glycoside;
stilbenoid		00low000000
acteoside
0
catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite		00low000000
josamycin
0
acetate ester;
aldehyde;
disaccharide derivative;
glycoside;
macrolide antibiotic;
tertiary alcohol;
tertiary amino compound		antibacterial drug;
metabolite		00low000000
rutin
0
flavonoids;
glycoside		00low000000
desoxyrhaponticin
0
glycoside;
stilbenoid		00low000000
juglanin
0
flavonoids;
glycoside		00low000000
kaempferol 3-o-neohesperidoside
0
flavonoids;
glycoside		00low000000
neoisoliquiritin
0
flavonoids;
glycoside		00low000000
4-[4-(4-hydroxy-3-methoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan-1-yl]-2-methoxyphenyl hexopyranoside
0
glycoside;
lignan		00low000000
Diosmetin rutinoside
0
flavonoids;
glycoside		00low000000
simmondsin
0
glycoside00low000000
icarrin
0
flavonoids;
glycoside		00low000000
vitexin rhamnoside
0
flavonoids;
glycoside		00low000000
epimedin b
0
flavonoids;
glycoside		00low000000
epimedin c
0
flavonoids;
glycoside		00low000000
hesperidin
0
flavonoids;
glycoside		00low000000
marein
0
flavonoids;
glycoside		00low000000
isoliquiritin apioside
0
flavonoids;
glycoside		00low000000
mulberroside a
0
glycoside;
stilbenoid		00low000000
2''-galloylhyperin
0
flavonoids;
glycoside		00low000000
sergliflozin etabonate
0
glycoside00low000000
7-monohydroxyethylrutoside
0
flavonoids;
glycoside		00low000000
remogliflozin etabonate
0
glycoside00low000000
ginsenoside rb1
0
ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger		00low000000
thiocolchicoside
0
glycoside00low000000
ginsenoside rg3
0
ginsenoside;
glycoside;
tetracyclic triterpenoid		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite		00low000000
goniothalesdiol
0
glycoside00low000000
sagittatoside b
0
flavonoids;
glycoside		00low000000
pumiloside
0
glycoside00low000000
kelampayoside a
0
glycosidemetabolite00low000000
4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid o-glucoside
0
glycoside00low000000
garcimangosone d
0
glycoside00low000000
Diosmetin 7-O-beta-D-glucopyranoside
0
flavonoids;
glycoside		00low000000
Asebotin
0
flavonoids;
glycoside		00low000000
Phenylethyl beta-D-glucopyranoside
0
glycoside00low000000
3-hydroxy-3-methyl-5-oxo-5-[[3,4,5-trihydroxy-6-[[6-methoxy-2-oxo-3-[(2-oxo-1-benzopyran-7-yl)oxy]-1-benzopyran-7-yl]oxy]-2-oxanyl]methoxy]pentanoic acid
0
coumarins;
glycoside		00low000000
asperulosidic acid
0
glycoside;
iridoid monoterpenoid		00low000000
verproside
0
glycosidemetabolite00low000000
5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-3-yl 6-O-(6-deoxyhexopyranosyl)hexopyranoside
0
flavonoids;
glycoside		00low000000
helicide
0
glycoside00low000000
5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-3-yl 2-O-hexopyranosylhexopyranoside
0
flavonoids;
glycoside		00low000000
Shanzhiside methyl ester
0
glycoside;
iridoid monoterpenoid		00low000000
3'',4''-Diacetylafzelin
0
flavonoids;
glycoside		00low000000
2-[1-[1-hydroxy-10,13-dimethyl-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-4,5-dimethyl-2,3-dihydropyran-6-one
0
glycoside;
withanolide		00low000000
cellulose
0
glycoside00low000000
salirepin
0
glycoside00low000000
didymin
0
flavonoids;
glycoside		00low000000
ethyl cellulose
0
glycoside00low000000
salicortin
0
glycoside00low000000
bacillithiol
0
glycoside;
monosaccharide derivative;
thiol		antioxidant;
bacterial metabolite;
cofactor		00low000000
multiflorin a
0
flavonoids;
glycoside		00low000000
typhaneoside
0
flavonoids;
glycoside		00low000000
vanilloloside
0
glycosidemetabolite00low000000
jadomycin b
0
glycoside;
jadomycin;
organic heteropentacyclic compound		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor;
bacterial metabolite		00low000000
(20R)-ginsenoside Rg3
0
ginsenoside;
glycoside;
tetracyclic triterpenoid		antioxidant;
plant metabolite		00low000000
5-hydroxytryptophol glucuronide
0
glycoside00low000000
coumermycin
0
aromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles		antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor		00low000000
ascorbic acid 2-o-glucoside
0
glycoside00low000000
opt 80
0
carboxylic ester;
glycoside;
macrolide antibiotic;
organochlorine compound;
phenols		antibacterial drug;
bacterial metabolite;
EC 2.7.7.6 (RNA polymerase) inhibitor		00low000000
pravastatin
0
glycoside;
lignan		00low000000
dehydrotomatine
0
alkaloid antibiotic;
glycoside;
steroid alkaloid;
tetrasaccharide derivative		antifungal agent;
phytotoxin;
plant metabolite		00low000000
vicine
0
glycoside00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
fenofibrate
1
aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic		202020204.0low000010
pioglitazone
1
aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic		202020204.0low000010
phlorhizin
1
aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite		201920195.0low000010
chenodeoxycholic acid
1
bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite		202020204.0low000010
fenofibric acid
1
aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite		202020204.0low000010
rosiglitazone
1
aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug		202020204.0low000010
tak 779
1
202020204.0low000010
obeticholic acid
1
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
dihydroxy-5beta-cholanic acid		farnesoid X receptor agonist;
hepatoprotective agent		202020204.0low000010
gft505
1
202020204.0medium000010
dapagliflozin
3
aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201820205.0low000030
gw 4064
1
stilbenoid202020204.0low000010
mbx-8025
1
202020204.0low000010
cenicriviroc
1
aromatic ether;
benzazocine;
diether;
imidazoles;
secondary carboxamide;
sulfoxide		anti-HIV agent;
anti-inflammatory agent;
antirheumatic drug;
chemokine receptor 2 antagonist;
chemokine receptor 5 antagonist		202020204.0low000010
empagliflozin
3
aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201820205.3low000030
1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol
3
diarylmethane201820205.0high000030
canagliflozin
3
C-glycosyl compound;
organofluorine compound;
thiophenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201820205.0low000030
azd7687
1
202020204.0low000010
pf 04971729
2
diarylmethane201820195.5low000020
deberza
2
2-benzofurans201820195.5high000020
a 769662
1
biphenyls202020204.0low000010
4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid
1
202020204.0medium000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
chlorine
1
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		201920195.0low000010
niacinamide
2
pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor		2012201610.0low000020
uracil
1
pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		201620168.0low100010
uric acid
3
uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite		201720205.7low100030
candesartan
1
benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		2014201410.0low000010
glimepiride
1
sulfonamide2012201212.0low100010
losartan
1
biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist		201820186.0low000010
metformin
19
guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic		201220235.7low14000127
nifedipine
1
C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent		2014201410.0low000010
pioglitazone
6
aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic		201220217.3low300051
sorbitol
3
glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent		201420217.0low000021
hydroxyproline
1
4-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite		201520159.0low000010
phlorhizin
4
aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite		201220198.2low000040
thiophenes
162
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent201120226.6high4000013923
pyrazines
1
diazine;
pyrazines		Daphnia magna metabolite2012201212.0low100010
thiazolidines
2
thiazolidine201720205.5low200020
fructosamine
1
2011201113.0low100010
fludrocortisone
1
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug		201620168.0low000010
glucose, (beta-d)-isomer
163
D-glucopyranoseepitope;
mouse metabolite		201120236.6high4100013924
triazoles
1
1,2,3-triazole2012201212.0low100010
febuxostat
1
1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor201820186.0low000010
moxifloxacin
1
aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug2013201311.0low100010
glycogen
1
201620168.0low000010
glycosides
2
2013201311.0low000020
topiroxostat
1
201820186.0low000010
dapagliflozin
17
aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201320237.1low1000143
alogliptin
1
nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		201620168.0low100010
sitagliptin phosphate
11
201220234.3low1000056
gw 2580
1
201820186.0low000010
empagliflozin
14
aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201320237.5low0000122
pituitrin
1
202020204.0low000010
glucagon
1
peptide hormone202220222.0low100001
liraglutide
1
lipopeptide;
polypeptide		glucagon-like peptide-1 receptor agonist;
neuroprotective agent		202120213.0low000001
glucagon-like peptide 1
2
201620225.0low100011
incretins
1
201620168.0low000010
c-peptide
3
201620187.0low300030
canagliflozin
17
C-glycosyl compound;
organofluorine compound;
thiophenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201320236.9low1000152
glycolipids
1
201820186.0low000010
piperidines
1
201620168.0low100010
natriuretic peptide, brain
2
polypeptide201920223.5low100011
insulin glargine
1
201720177.0low100010
allopurinol
1
nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger		201820186.0low000010
leptin
3
201620215.3low000021
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acetonemia0
1
201720177.0low000010
Acidosis, Diabetic0
1
201920195.0low000010
Acute Kidney Failure0
1
201920195.0low000010
Acute Kidney Injury0
1
201920195.0low000010
Adverse Drug Event0
1
202020204.0low000010
Albuminuria0
1
2014201410.0low000010
Alloxan Diabetes0
20
201220226.6low0000173
Arterial Diseases, Carotid0
1
201620168.0low100010
Asymmetric Diabetic Proximal Motor Neuropathy0
1
201620168.0low000010
Atherogenesis0
1
201720177.0low000010
Atherosclerosis0
1
201720177.0low000010
Autoimmune Diabetes0
11
201220215.5low400083
Blood Pressure, High0
3
201720186.3low000030
Blood Pressure, Low0
1
202020204.0low000010
Body Weight0
28
201320196.8low8000280
Bone Fractures0
1
201920195.0low000010
Brain Injuries, Traumatic0
1
201620168.0low000010
Breast Cancer0
1
202020204.0low000010
Breast Neoplasms0
1
202020204.0low000010
Cancer of Esophagus0
1
201620168.0low000010
Cardiac Failure0
5
201520226.0low100041
Cardiometabolic Syndrome0
1
202020204.0low000010
Cardiovascular Diseases0
2
201720186.5low100020
Carotid Artery Diseases0
1
201620168.0low100010
Choline Deficiency0
1
201520159.0low000010
Chronic Kidney Diseases0
7
201320235.7low200061
Cirrhoses, Experimental Liver0
1
201620168.0low000010
Cirrhosis0
1
201920195.0low000010
Cirrhosis, Liver0
3
201520226.3low000021
Deep Vein Thrombosis0
1
201820186.0low000010
Dermatitis Medicamentosa0
1
201720177.0low000010
Dermatoses0
2
201820186.0low000020
Diabetes Mellitus1
8
201520225.5low000062
Diabetes Mellitus, Adult-Onset0
121
201120236.7medium4000010120
Diabetes Mellitus, Type 11
11
201220215.5low400083
Diabetes Mellitus, Type 21
121
201120236.7medium4000010120
Diabetic Angiopathies0
2
201620206.0low200020
Diabetic Glomerulosclerosis0
8
201620215.5low100071
Diabetic Ketoacidosis0
1
201920195.0low000010
Diabetic Nephropathies0
8
201620215.5low100071
Diabetic Neuropathies0
1
201620168.0low000010
Diabetic Retinopathy0
1
201620168.0low000010
Disease Exacerbation0
3
201620196.3low000030
Disease Models, Animal0
11
201220225.6low000074
Drug Overdose0
1
202020204.0low000010
Drug-Related Side Effects and Adverse Reactions0
1
202020204.0low000010
Encephalopathy, Traumatic0
1
201620168.0low000010
Esophageal Neoplasms0
1
201620168.0low000010
Fasting Hypoglycemia0
8
201320217.6low300071
Fatty Liver0
5
201320236.8low100041
Fatty Liver, Nonalcoholic0
16
201520225.2low2000115
Fibrosis0
1
201920195.0low000010
Fractures, Bone0
1
201920195.0low000010
Genital Tract Infections0
1
201620168.0low100010
Glucose Intolerance0
1
2014201410.0low000010
Glycosuria0
12
201120198.8low2000120
Glycosuria, Renal0
1
2013201311.0low000010
Heart Failure0
5
201520226.0low100041
Hyperglycemia0
11
201120208.4low3000110
Hyperglycemia, Postprandial0
11
201120208.4low3000110
Hyperlipemia0
2
2013201410.5low000020
Hyperlipidemias0
2
2013201410.5low000020
Hyperphagia0
1
201620168.0low000010
Hypertension0
3
201720186.3low000030
Hyperuricemia0
1
201820186.0low000010
Hypoglycemia0
8
201320217.6low300071
Hyponatremia0
1
201620168.0low000010
Hypotension0
1
202020204.0low000010
Impaired Glucose Tolerance0
1
2014201410.0low000010
Inflammation0
4
2013201510.2low000040
Injury, Myocardial Reperfusion0
1
201920195.0low000010
Innate Inflammatory Response0
4
2013201510.2low000040
Insulin Resistance0
14
201320227.1low2000131
Insulin Sensitivity0
14
201320227.1low2000131
Kidney Diseases0
3
201820186.0low000030
Kidney Failure0
2
201420159.5low100020
Lipodystrophy0
1
201720177.0low000010
Liver Cirrhosis0
3
201520226.3low000021
Liver Steatosis0
5
201320236.8low100041
Metabolic Syndrome0
1
202020204.0low000010
Non-alcoholic Fatty Liver Disease0
16
201520225.2low2000115
Obesity0
16
201320236.8low0000151
Pulmonary Arterial Remodeling0
1
201920195.0low000010
Renal Insufficiency0
2
201420159.5low100020
Renal Insufficiency, Chronic0
7
201320235.7low200061
Skin Diseases0
2
201820186.0low000020
Urinary Tract Infections0
2
201620196.5low100020
Vascular Injuries0
1
201920195.0low000010
Venous Thrombosis0
1
201820186.0low000010
Weight Loss0
8
201420197.6low100080
Weight Reduction0
8
201420197.6low100080

Safety/Toxicity (27)

ArticleYear
Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.
Clinical drug investigation, , Volume: 43, Issue:12		2023
Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database.
Expert opinion on drug safety, , Volume: 22, Issue:8
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Diabetes, obesity & metabolism, , Volume: 23, Issue:9		2021
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Diabetes, obesity & metabolism, , Volume: 23, Issue:6		2021
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Expert opinion on pharmacotherapy, , Volume: 22, Issue:3		2021
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Drug discoveries & therapeutics, , Volume: 13, Issue:6		2019
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Journal of diabetes investigation, , Volume: 11, Issue:3		2020
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Diabetes, obesity & metabolism, , Volume: 21, Issue:10		2019
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
BMJ open, , 02-01, Volume: 9, Issue:1		2019
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Advances in therapy, , Volume: 36, Issue:4		2019
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Journal of diabetes investigation, , Volume: 10, Issue:5		2019
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Journal of diabetes investigation, , Volume: 10, Issue:5		2019
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Diabetes research and clinical practice, , Volume: 146		2018
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Diabetes, obesity & metabolism, , Volume: 20, Issue:10		2018
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Endocrine journal, , Aug-27, Volume: 65, Issue:8		2018
Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Expert opinion on pharmacotherapy, , Volume: 19, Issue:4		2018
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Expert opinion on pharmacotherapy, , Volume: 19, Issue:3		2018
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV
BMJ open, , 05-09, Volume: 7, Issue:5		2017
Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Expert opinion on pharmacotherapy, , Volume: 17, Issue:15		2016
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Expert opinion on pharmacotherapy, , Volume: 17, Issue:15		2016
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Diabetes, obesity & metabolism, , Volume: 18, Issue:12		2016
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Journal of diabetes investigation, , Volume: 7, Issue:3		2016
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Journal of diabetes investigation, , Volume: 7, Issue:4		2016
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Diabetes, obesity & metabolism, , Volume: 17, Issue:2		2015
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
Journal of diabetes and its complications, , Volume: 27, Issue:3
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Diabetes, obesity & metabolism, , Volume: 15, Issue:5		2013
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Diabetes technology & therapeutics, , Volume: 13, Issue:12		2011

Long-term Use (2)

ArticleYear
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Journal of diabetes investigation, , Volume: 10, Issue:5		2019
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.
Drug discoveries & therapeutics, , Mar-19, Volume: 12, Issue:1		2018

Pharmacokinetics (13)

ArticleYear
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Clinical therapeutics, , Volume: 42, Issue:9		2020
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Physiological reports, , Volume: 8, Issue:2		2020
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
American journal of physiology. Renal physiology, , 09-01, Volume: 315, Issue:3		2018
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Expert opinion on pharmacotherapy, , Volume: 18, Issue:14		2017
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Journal of pharmacological sciences, , Volume: 130, Issue:3		2016
A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Sep-01, Volume: 1000		2015
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Clinical pharmacokinetics, , Volume: 54, Issue:7		2015
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Drugs, , Volume: 75, Issue:1		2015
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Clinical pharmacokinetics, , Volume: 53, Issue:11		2014
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Diabetes research and clinical practice, , Volume: 106, Issue:1		2014
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Clinical drug investigation, , Volume: 33, Issue:7		2013
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Diabetes, obesity & metabolism, , Volume: 14, Issue:10		2012
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Diabetes technology & therapeutics, , Volume: 13, Issue:12		2011

Dosage (10)

ArticleYear
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Heart and vessels, , Volume: 35, Issue:9		2020
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Clinical drug investigation, , Volume: 36, Issue:4		2016
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Clinical pharmacokinetics, , Volume: 54, Issue:7		2015
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Drugs, , Volume: 75, Issue:1		2015
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Clinical pharmacokinetics, , Volume: 53, Issue:11		2014
Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Clinical therapeutics, , Volume: 35, Issue:8		2013
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Journal of pharmacological sciences, , Volume: 120, Issue:1		2012
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Diabetes, obesity & metabolism, , Volume: 14, Issue:10		2012
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 385, Issue:4		2012
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Clinical drug investigation, , Dec-01, Volume: 31, Issue:12		2011

Interactions (4)

ArticleYear
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
European journal of pharmacology, , Jun-15, Volume: 901		2021
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Journal of diabetes investigation, , Volume: 12, Issue:2		2021
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Clinical and experimental pharmacology & physiology, , Volume: 42, Issue:1		2015
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Diabetes, obesity & metabolism, , Volume: 17, Issue:3		2015